Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Colorectal Neoplasms 26Neoplasm Metastasis 7Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Advanced Solid Tumors 2Thyroid Neoplasms 1Recurrence Free Survival 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Histiocytosis 1Glioma 1Fallopian Tube Neoplasms 1Erythema 1Endometrial Neoplasms 1Edema 1Dihydropyrimidine Dehydrogenase Deficiency 1Colorectal Cancer Metastatic 1Cholangiocarcinoma 1

Interventions

pembrolizumab 1Taxes 1Sirolimus 1Panitumumab 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Erythema × Panitumumab × 1 year × Clear all
NCT02876107 2026-04-15

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
42 enrolled
Breast

Breast Neoplasms, Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡